Drug-induced toxicity remains one of the leading causes of discontinuation of the drug candidate and post-marketing withdrawal. Thus, early identification of the drug candidates with the potential for toxicity is crucial in the drug development process. With the recent discovery of human- Induced Pluripotent Stem Cells (iPSC) and the establishment of the differentiation protocol of human iPSC into the cell types of interest, the differentiated cells from human iPSC have garnered much attention because of their potential applicability in toxicity evaluation as well as drug screening, disease modeling and cell therapy. In this review, we expanded on current information regarding the feasibility of human iPSC-derived cells for the evaluation of drug-induced toxicity with a focus on human iPSCderived hepatocyte (iPSC-Hep), cardiomyocyte (iPSC-CMs) and neurons (iPSC-Neurons). Further, we CSAHi, Consortium for Safety Assessment using Human iPS Cells, reported our gene expression profiling data with DNA microarray using commercially available human iPSC-derived cells (iPSC-Hep, iPSC-CMs, iPSC-Neurons), their relevant human tissues and primary cultured human cells to discuss the future direction of the three types of human iPSC-derived cells.

药物引起的毒性仍然是停用候选药物和上市后撤回药物的主要原因之一。因此，在药物开发过程中，尽早识别具有潜在毒性的候选药物至关重要。随着人类诱导多能干细胞（iPSC）的最新发现以及人类iPSC分化为目标细胞类型的分化方案的建立，来自人类iPSC的分化细胞因其潜在的毒性评估潜力而备受关注。以及药物筛选，疾病建模和细胞疗法。在这篇综述中，我们扩展了有关人iPSC衍生细胞在评估药物诱导的毒性方面的可行性的最新信息，重点是人iPSC衍生的肝细胞（iPSC-Hep），心肌细胞（iPSC-CMs）和神经元（iPSC-Neurons）。此外，我们使用人类iPS细胞的安全性评估协会CSAHi报告了DNA微阵列的基因表达谱数据，其中使用了市售的人类iPSC衍生细胞（iPSC-Hep，iPSC-CM，iPSC-Neurons），其相关的人体组织和原代培养的人类细胞，以讨论三种类型的人类iPSC衍生细胞的未来方向。